You are here

FDA Approves Tecovirimat To Treat Smallpox

The move is considered part of the antiterrorism effort.

The World Health Organization declared smallpox to be eradicated way back in 1980. However, many antiterrorism experts worry that radical groups can use the disease to wipe out populations who may never have been inoculated against it. That helps explain the attention the FDA received when it approved tecovirimat (TPOXX) on July 13 to treat smallpox. FDA Commissioner Scott Gottlieb said in a statement: “This new treatment affords us an additional option should smallpox ever be used as a bioweapon.” Tecovirimat is the first drug the FDA has approved that has an indication as a treatment for smallpox.

The FDA had granted tecovirimat’s application Fast Track, Priority Review, and Orphan Drug designations. It also gave the drug a Material Threat Medical Countermeasure Priority Review voucher.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential